Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel oral small molecule GLP-1 receptor agonist (HRS-7535) in healthy subjects

被引：0

作者：

Wu, J. ^{[1
]}

Hu, W. ^{[1
]}

Du, Y. ^{[1
]}

Zhang, Q. ^{[1
]}

Zhou, R. ^{[1
]}

Zhang, Q. ^{[1
]}

Qin, H. ^{[1
]}

Ye, Z. ^{[2
]}

Xu, Y. ^{[2
]}

Feng, S. ^{[2
]}

Shu, C. ^{[2
]}

Shen, Y. ^{[2
]}

Fan, Y. ^{[2
]}

机构：

[1] Anhui Med Univ, Phase I Clin Trial Ctr, Affiliated Hosp 2, Hefei, Peoples R China

[2] Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China

来源：

DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

629

引用

页码：S316 / S317

页数：2

共 50 条

[1] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Small Molecule GLP-1 Receptor Agonist (HRS-7535) in Healthy Subjects -A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study
Wu, Jingying
Hu, Wei
Du, Yijun
Zhang, Qian
Zhou, Renpeng
Zhang, Qin
Qin, Huiling
Ye, Zi
Xu, Yimei
Feng, Sheng
Shu, Chang
Shen, Yu
Fan, Yang
[J]. DIABETES, 2023, 72
[2] Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a dual GLP-1/GIP receptor agonist (HRS9531) in healthy subjects
Wen, Q.
He, K.
Wei, F.
Chen, H.
Zhang, Y.
Sheng, Z.
Yin, L.
[J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S326 - S327
[3] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Ultra-Long-Acting GLP-1 Receptor Agonist (ZT002) in Healthy Subjects
Zhang, Yuanyuan
Xu, Xiusen
McLendon, Kristi
Wong, Alex H. L.
Zhang, Yuying
Zhang, Xujia
[J]. DIABETES, 2024, 73
[4] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of Amg 986, a Novel Small Molecule Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients
Hellawell, Jennifer
Abbasi, Siddique
Trivedi, Ashit
Tsirtsonis, Kate
Kaufman, Allegra
[J]. JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S68 - S68
[5] A First-in-Human Single- and Multiple-Ascending Dose Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Novel Oral Nonpeptide GLP-1 Receptor Agonist in Healthy Subjects
Pratt, Edward J.
Ma, Xiaosu
Liu, Rong
Robins, Deborah A.
Sloop, Kyle
Benson, Charles
[J]. DIABETES, 2022, 71
[6] Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of the Novel Dual GIP/GLP-1 Agonist (RG7697) after Single Subcutaneous Administration in Healthy Subjects
Portron, Agnes
Jadidi, Shirin
Sarkar, Neena
Dimarchi, Richard
Schmitt, Christophe
[J]. DIABETES, 2017, 66 : A624 - A624
[7] Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Dual GLP-1/Glucagon Agonist SAR425899 in Healthy Subjects and Diabetes Patients
Tillner, Joachim
Posch, Maximillian G.
Hueser, Andreas
Teichert, Lenore
Einig, Christine
Bergmann, Karin
Keil, Stefanie
Rimbault, Mathieu
Larsen, Philip Just
Lorenz, Martin
[J]. DIABETES, 2016, 65 : A6 - A7
[8] Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial
Wu, Jingying
Zhou, Renpeng
Zhang, Qian
Zhang, Qin
Qin, Huiling
Ye, Zi
Xu, Yimei
Feng, Sheng
Shu, Chang
Shen, Yu
Fan, Yang
Wang, Quanren
Du, Yijun
Hu, Wei
[J]. DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 901 - 910
[9] Tolerability, Safety, and Pharmacokinetics of Once-Weekly Administration of GLP-1 Analogue in Healthy Subjects
Xu, Michael M.
[J]. DIABETES, 2015, 64 : A72 - A73
[10] Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Orforglipron (LY3502970), an Oral, Nonpeptide GLP-1 Receptor Agonist
Ma, Xiaosu
Liu, Rong
Pratt, Edward J.
Benson, Charles
Bhattachar, Shobha N.
[J]. DIABETES, 2023, 72

← 1 2 3 4 5 →